Administration of beta-lactam antimicrobials by continuous infusion has been proposed as an intervention to improve pharmacokinetic/pharmacodynamic target attainment of these compounds in patients with severe sepsis and septic shock.

This study will be powered to mortality (an important patient-centred outcome). The proposed clinical study will be submitted to the NHMRC for Project Grant funding consideration in 2016 as well as to Canadian and European funding bodies.